News

Under the terms of the agreement, VWR will continue to sell and promote Pall’s filtration technologies to VWR customers in the US, Canada, Puerto Rico and throughout Europe.

This patent extends through the year 2022. Tobramycin inhalation powder (TIP) is being co-developed by Nektar and Novartis and is currently in Phase III development for the prevention

Under the terms of the license agreement with Bayer, ACT has acquired an anti-angiogenic receptor tyrosine kinase inhibitor entering Phase II clinical studies for colorectal cancer, amongst other

A double-blind, parallel-group, placebo-controlled Phase III study to evaluate the safety and efficacy of Lexapro, was conducted in multiple centers across the US. The primary endpoint was change

As part of the agreement, ImClone will utilize Champions Biotechnology’s Biomerk Tumorgrafts in the initial preclinical evaluation. Doug Burkett, president of Champions Biotechnology, said: “Studies suggest that our

Aquashunt is an implantable physiologic device that is designed to address the shortcomings of current glaucoma treatments. It is intended to reduce intraocular pressure physiologically by allowing excess

Menarini is seeking approval of Factive for the treatment of community-acquired pneumonia, acute bacterial exacerbations of chronic bronchitis and acute bacterial sinusitis. The regulatory review time in Europe

ARRY-797 has achieved its primary and secondary endpoints for analgesic effect and was well-tolerated in this phase II clinical trial. The analgesic effect of 400mg of ARRY-797 administered

In these roles, Mr Holtz will be responsible for oversight of the controller’s group, treasury, risk management and information technology reporting to Thomas Gardner, chairman and CEO of